Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07661823

QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (Quantum AI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360)

BRIEF SUMMARY

A. "What is the purpose of this study?"

This study will test whether the "AI City Hall Project" (QAIAx), a quantum artificial intelligence (AI) public health agency, can provide free or low-cost behavioral and mental health services inside self-contained, dome-enclosed communities called "Microcities". Researchers want to see if AI-managed public administration, AI humanoid robots, holoportation of human-figures via 'holo-suites' (e.g., AI-119 Kikkeri Holo-Suit; AI-119 Vulcan QM-Ware) and advanced AI mental-health tools can lower housing and care costs, improve mental health outcomes (e.g., particular ecosystems using AI tools among persons with one or more addiction disorders), and be financially sustainable for people on fixed incomes or public assistance.

B. "What conditions does the study focus on?"

The study focuses on adults with:

* Autism spectrum disorders (Asperger's, autism, ADHD, ASD) * Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA/ecstasy, tobacco/nicotine) * Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders) * Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).

C. "What does the study involve?"

Eligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital "attitude inoculation" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.

**Who can participate?**

You may be able to join if you:

* Are an adult (18 years or older) * Have a diagnosis of one of the listed mental-health or addiction disorders * Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organization (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole/probation officer, judge) * Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.

Participants who are veterans, receive public assistance (e.g., VA disability, SSDI/SSI, Medicaid, Medicare), or are experiencing homelessness may be prioritized.

**Where is the study taking place?** The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.

**Who is sponsoring the study?** The study is sponsored by Veterans Recovery Network Inc., a SCDV-owned non-profit organization, in collaboration with AI-119 Vulcan Project Research & Educational Technology Co. (PRETCO). The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §§§§ 4001, 4021, 4022, and 4023) and is part of a Cooperative Research and Development Agreement (CRADA) with participating segments or RDT&E programming missions of the United States Defense Department (DoW).

This summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Asperger's Disorder ADHD ADHD - Attention Deficit Disorder With Hyperactivity ASD Abstinence, Sex Addiction Disorders Alcohol Abuse/Dependence Alcohol Addiction Alcohol and Other Drug Use Disorders Alcohol and Other Substance Use Prevention Alcohol-Related Disorders Alcoholism Anger Problems Asperger Disorder Asperger Syndrome Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Autism Autism Disorder Autism Spectrum Disorder Autistic Disorder Behavior Behavior, Addictive Chemically-Induced Disorders Child Abuse, Sexual Child Development Disorders, Pervasive Cocaine Abuse Cocaine-Related Disorders Coitus Compulsive Behavior Compulsive Sexual Behavior Disorder Disruptive, Impulse Control, and Conduct Disorders Eating Behavior Disorders Gambling Gambling Addiction Gambling Disorder Gender Dysphoria Gender Dysphoria, Adult Genital Diseases Homeless and Low Incomes People, Refugees Homelessness Impulsive Behavior MDMA ('Ecstasy') Marijuana Abuse Marijuana Abuse and Dependence Marijuana Use Disorder Mental Disorders Narcissism Narcotic Addiction Narcotic-Related Disorders Neurodevelopmental Disorders Opiate Substitution Treatment Opioid Abuse (Disorder) Opioid Abuse and Addiction Opioid-Related Disorders Psychedelic Drug Dependence Psychedelic Effects in Healthy Volunteers Psychedelic Experiences Psychiatric Disorder Reliability and Validity Risk-Taking Sex Abuse Sex Behavior Sex Crimes Sex Disorder Sex Disorders Sexual Abstinence Sexual Behavior Sexual Dysfunction, Physiological Sexual Dysfunctions, Psychological Sexual and Gender Disorders Smoking Smoking (Tobacco) Addiction Smoking Abstinence Smoking Among Youth Substance-Related Disorders Urogenital Diseases

Age range

17 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Administrative Office

Richmond, Virginia, 23219, United States

About this study

  • PROGRAM OVERVIEW & MISSION

A. Statutory Authority and Mission

The QAIAx Clinical Trial (NIH PSR ID: NCT07661823) is a large-scale, multi-year Research, Development, Test, and Evaluation (RDT&E) program conducted under the authority of 10 U.S.C. §§§§ 4001, 4021, 4022, and 4023, utilizing Other Transaction Authority (OTA). This framework establishes specialized RDT&E enclaves, designated as "Microcities," on closed U.S. military installations, designated research sites (e.g., FFRDC, UARC, Enhanced Use Lease (EUL under Permanent Air-Gapped Enclosures - 10 U.S.C. 2667, 10 U.S.C. 2808a), tribal lands (ISDEAA collaborative; e.g., private-fee land or temporary DoD easement), or global special economic zones in nexus with active bilateral treatise as ).

B. Program Mission The mission is to evaluate whether a quantum artificial intelligence public health agency, utilizing non-medicinal AI robotics, can deliver free or low-cost behavioral and mental health services within self-contained, dome-enclosed communities. This "AI City Hall Project" leverages AI-managed public administration, AI humanoid robots, and holoportation remote command to serve individuals on fixed incomes or public assistance.

C. Trial Scale and Pre-Launch Status Total Enrollment: The multi-year study targets a total enrollment of 1,000,000 participants across a global network of 300 Microcities.

Capacity: Each facility will house between 1,500 and 15,000 occupants. The initial live-in phase requires 50,000 patients and 5,000 trainees.

Timeline: Operations are scheduled to run from early 2027 through the end of 2028. The project remains in a pre-launch phase until 1 July 2027.

Coordination: A pre-launch coordination sync will occur via Zoom on September 27, 2026 to announce initial enclave sponsors, microcity locations, enrollment execution data, and other critical updates about the clinical trial.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals aged 17 to 99 years old.
  • Referral by a licensed health services professional (e.g., R.N., N.P., Ph.D., M.D.).
  • Referral by a non-profit organization (e.g., 501c3, university, church).
  • Referral by a public agency (e.g., case manager, social worker, parole/probation/PTS officer, judge).

Exclusion criteria

  • Individuals under 17 or over 99 years of age.

Treatment and study plan

AI City Hall Project (AIhealth4u - Public Health Central)

Behavioral

QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64/074,526, 64/063,557, 63/903,181, 63/729,428: A quantum AI public health agency that provides free public health services to registered and sponsored visitors/occupants for RDT&E under 28 U.S. Code 1498 (classified as a PPA under 10 U.S. Code 129a). AI Public Health Central Microcity will focus on behavioral and psychiatric health for patients with various common mental health and addiction disorders, placed in monitored ecosystems with AI/AGI tools managing public administration resources under statistical surveys to determine to determine which fiscal viability, effectiveness and accuracy AI/AGI Health tools for mental health treatment (e.g., AI robotics; 'Quasi-Mind Ware' and Mental Health/Psychiatric Cyber-Medicine treatment applying AI Symbiosis, e.g., See 'Traum-to-Real' installation of generative AI memory into the human mind via attitude inoculation)

AI City Hall Project (QAIAx Microcity A - AI Public Health Central)

Behavioral

QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64/074,526, 64/063,557, 63/903,181, 63/729,428: A quantum AI public health agency that provides free public health services to registered and sponsored visitors/occupants for RDT&E under 28 U.S. Code 1498 (classified as a PPA under 10 U.S. Code 129a)

Primary outcomes

  1. Vulcan QAIAx v4.0x (Beta ISAC) for AI-119 and AI Wat (1498) patent series for Private, Public, and Military sectors (Change from Baseline in Participant Lifestyle Efficiency, Behavioral Stability, & Sovereign Resource Allocation via Vulcan QAIAx v4.0)

    Time frame: Baseline enrollment, month 12, and month 24 (tracked monthly)

    This comprehensive description bridges the clinical parameters of the AI-119 Vulcan SOF Program (an AGI/AI Ecosystems RDT&E Program launched under the 119th U.S. Congress) and Veterans Recovery Network Program (VA-authorized program, est. 2020, Richmond VAMC) with the high-velocity public, private, and military administrative functions optimized by the AI-119 and AI Wat patent series under 28 U.S.C. § 1498 (Government Use of Patents), using a Omni-AI robotics among Holo-Suit, Quasi-Mind Ware (QM-Ware), Body-Ware, QAIA Humanoid (via "AI-Me" Hybrid AI Symbiote app). This primary outcome measures the definitive capacity of the Vulcan QAIAx v4.0x (Beta ISAC) autonomous platform to generate an efficient lifestyle, stabilize severe psychiatric and addiction disorders, and optimize administrative resource delivery across Private, Public, and Military sector frameworks. Utilizing a '90/10' hybrid workforce model (90% omni-AI Humanoid Workforce / 10% Human Auditor & Administrator oversight).

  2. Change from Baseline in Participant Lifestyle Efficiency and Behavioral Stability Index (via QAIAx 4.0x Core Analytics)

    Time frame: Baseline enrollment, month 12, and month 24 (tracked monthly)

    The primary outcome directly track the core clinical and lifestyle stabilization of the veterans residing in the monitored Microcity ecosystem, measuring the effectiveness of the advanced AI/AGI tools. Total duration (measured in months vs. the traditional multi-year trajectories) and accuracy rate of AI-driven legal/health document processing, error corrections, and intake evaluations managed by the 90% AI Humanoid Workforce under human auditor ethical oversight under 'Kikkeri doctrine' to 'hire a million to skill a billion.'

Secondary outcomes

  1. Economic Sustainability and Housing Retention Cost Index under the Omni-AI Microcity Model

    Time frame: Baseline enrollment, month 12, and month 24 (tracked monthly)

    Total financial variance and cost-mitigation rates achieved by housing occupants within the $100 to $2,000 per month extreme-affordability bracket (including digital device provisioning and logistics integration), evaluated against standard public healthcare and federal housing expenditure benchmarks.

Study contacts

Contact information is provided by the study sponsor or research team.

C Peterson, Administrator

CONTACT

[email protected]

804-390-5037

RDTE Administrator

CONTACT

[email protected]

888-307-8380

Sponsors and collaborators

Lead sponsor

Veterans Recovery Network Inc.

Other

Collaborators

  • AI-119 Vulcan Project Research & Educational Technology Company (fka Henry Nanpei Academy Project)
  • Central Virginia VA Health Care System
  • U.S. Special Operations Command

Registry information

Official study title

QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (UPSTO App No(s). 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428) is Frontier AI/AGI Public Health Trials Sandbox Framework That Provides Free Public Health Services to Registered and Sponsored Visitors/Occupants for RDT&E Under 28 U.S.C. 1498 (Classified as a PPA, OTA Under 10 U.S. Code 4001, 4022), Serving as a Global Intranet of Humans Resident Patients Among Multiple Enclave Communicates ("AI Microcities" or "Smart Health Cities") Living and Learning With AI Robotics for Non-medicinal Treatment.

Acronym: QAIAx

Important dates

Study start
2026
Primary completion
2045
Study completion
2045
First posted
Jun 22, 2026
Registry last updated
Sep 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.